BHVN
Biohaven Ltd.11.03
-0.25-2.22%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
1.46BP/E (TTM)
-Basic EPS (TTM)
-7.52Dividend Yield
0%Recent Filings
10-Q
8-K
8-K
FDA skips advisory for troriluzole
Biohaven Ltd. received FDA notification on August 21, 2025, that no advisory committee meeting is required for its troriluzole NDA targeting Spinocerebellar Ataxia in adults. This follows a three-month PDUFA extension from May 2025 to review recent submissions. The decision streamlines the process. FDA approval remains on track for Q4 2025.
8-K
Biohaven amends Knopp deal
Biohaven Ltd. filed a prospectus supplement on August 15, 2025, enabling resale of 3,588,688 common shares issued to a selling shareholder under the May 1, 2024 Knopp Amendment. This amendment swapped scaled high single-digit to low-teens royalties for mid-single-digit flat royalties on BHV-7000 and pipeline programs, while slashing success milestones from up to $1,137.5 million to $270 million, with $25 million already paid. The deal streamlines payments, favoring cash or shares at Biohaven's option. Yet risks linger if approvals falter.
8-K
Biohaven Q2 results and pipeline
Biohaven reported Q2 2025 financials on August 11, showing a net loss of $198.1 million, down from $319.8 million last year, thanks to no repeat of a big one-time expense, while R&D costs hit $184.4 million amid pipeline pushes. Cash reserves stand at $408.2 million, funding key advances like VYGLXIA's SCA NDA nearing FDA decision in Q4 2025 and degraders BHV-1300 and BHV-1400 slashing IgG and Gd-IgA1 by up to 87% and 81%. Pipeline momentum builds. Yet regulatory approval remains uncertain.
ABVC
ABVC Biopharma, Inc.
2.06-0.01
BIIB
Biogen Inc.
171.50-4.24
BIVI
BioVie Inc.
1.43+0.00
BMRN
BioMarin Pharmaceutical Inc.
51.77-0.35
BTAI
BioXcel Therapeutics, Inc.
1.88+0.01
DRUG
Bright Minds Biosciences Inc.
93.99+8.32
IMVT
Immunovant, Inc.
26.61+0.61
TVGN
Tevogen Bio Holdings Inc.
0.38-0.01
ZBIO
Zenas BioPharma, Inc.
36.89+4.30
ZURA
Zura Bio Limited
4.12+0.05